|
|
|
| Effect of lncRNA PANDAR on Cisplatin chemosensitivity of cervical cancer cells and Cisplatin-resistant cells |
| ZHU Qian1,2 ZHANG Ling3 YUAN Peng2 LI Yu4 ZHANG Wei1 YANG Hong1 |
1.Department of Gynecology, Xijing Hospital, the First Affiliated Hospital of Air Force Military Medical University, Shaanxi Province, Xi′an 710032, China;
2.Ward One, Department of Gynecology, Northwest Women′s and Children′s Hospital, Shaanxi Province, Xi′an 710032, China;
3.Department of Gynecology and Endocrinology, Northwest Women′s and Children′s Hospital, Shaanxi Province, Xi′an 710032, China;
4.Department of Biochemical Teaching and Research of Air Force Military Medical University, Shaanxi Province, Xi′an 710032, China |
|
|
|
Abstract Objective To explore the effect of lncRNA PANDAR on the resistance and sensitivity of Cisplatin in cervical cancer cells. Methods Human cervical cancer Cisplatin-resistant cells named HeLa-DDP were constructed. The parent HeLa and HeLa-DDP cells were stimulated with 1, 2, 4, 8, 16 μg/mL doses of Cisplatin. The recombinant PANDAR vectors or lentiviral plasmid of sh-PANDAR were transfected into HeLa-DDP and HeLa cells. All cells were divided into different groups: control group, vector group, PANDAR group, sh-NC group and sh-PANDAR group. Then, PANDAR expression was detected by qRT-PCR. CCK-8 assay was conducted to determine cell viability. Cell apoptosis was analyzed by flow cytometry. Results HeLa-DDP cells exhibited stronger resistance to Cisplatin relative to parent HeLa cells (P < 0.05). In contrast to parent HeLa cells, PANDAR expression was decreased in HeLa-DDP cells (P < 0.05). Overexpression of PANDAR inhibited cell viability under Cisplatin exposure in HeLa-DDP cells relative to control groups (P < 0.05), concomitant with increases in cell apoptosis (P < 0.05). Whilst, PANDAR cessation enhanced cell viability in HeLa-DDP cells under Cisplatin exposure (P < 0.05). Additionally, PANDAR knockdown increased HeLa cell viability upon Cisplatin conditions (P < 0.05). Conclusion PANDAR may regulate cell resistance to Cisplatin in HeLa-DDP and HeLa cells.
|
|
|
|
|
|
[1] Torre LA，Islami F，Siegel RL，et al. Global Cancer in Women：Burden and Trends [J]. Cancer Epidemiol Biomarkers Prev，2017，26（4）：444-457.
[2] Allemani C，Weir HK，Carreira H，et al. Global surveillance of cancer survival 1995-2009：analysis of individual data for 25，676，887 patients from 279 population-based registries in 67 countries (CONCORD-2) [J]. Lancet，2015， 385（9972）：977-1010.
[3] Kumar L，Harish P，Malik PS，et al. Chemotherapy and targeted therapy in the management of cervical cancer [J]. Curr Probl Cancer，2018，42（2）：120-128.
[4] Espina M，Corte-Rodriguez M，Aguado L，et al. Cisplatin resistance in cell models：evaluation of metallomic and biological predictive biomarkers to address early therapy failure [J]. Metallomics，2017，9（5）：564-574.
[5] 刘红，张国楠.宫颈癌化疗耐药相关问题[J].中国实用妇科与产科杂志，2015，31（3）：198-201.
[6] 刘宁，成冬冬，姜金波.长链非编码RNA PANDAR促进结直肠癌转移的作用和机制研究[J].中国癌症杂志，2017，27（4）：268-275.
[7] Ma PJ，Guan QK，Xu DW，et al. LncRNA PANDAR as a prognostic marker in Chinese cancer [J]. Clin Chim Acta，2017，475：172-177.
[8] Liu J，Ben Q，Lu E，et al. Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cance [J]. Cell Death Dis，2018，9（2）：168.
[9] Zhu H，Luo H，Zhang W，et al. Molecular mechanisms of Cisplatin resistance in cervical cancer [J]. Drug Des Devel Ther，2016，10：1885-1895.
[10] Bhan A，Soleimani M，Mandal SS. Long Noncoding RNA and Cancer：A New Paradigm [J]. Cancer Res，2017，77（15）：3965-3981.
[11] Ma Y，Zhang J，Wen L，et al. Membrane-lipid associated lncRNA：A new regulator in cancer signaling [J]. Cancer Lett，2018，419：27-29.
[12] Renganathan A，Felley-Bosco E. Long Noncoding RNAs in Cancer and Therapeutic Potential [J]. Adv Exp Med Biol，2017，1008：199-222.
[13] Cai Z，Xu K，Li Y，et al. Long noncoding RNA in liver cancer stem cells [J]. Discov Med，2017，24（131）：87-93.
[14] Momen-Heravi F，Bala S. Emerging role of non-coding RNA in oral cancer [J]. Cell Signal，2018，42：134-143.
[15] Dasari S，Tchounwou PB. Cisplatin in cancer therapy：molecular mechanisms of action [J]. Eur J Pharmacol，2014，740：364-378.
[16] Rivandi M，Pasdar A，Hamzezadeh L，et al. The prognostic and therapeutic values of long noncoding RNA PANDAR in colorectal cancer [J]. J Cell Physiol，2019，234（2）：1230-1236.
[17] Yang L，Zhou JD，Zhang TJ，et al. Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia [J]. Cancer Manag Res，2018，10：4999-5007.
[18] Huang HW，Xie H，Ma X，et al. Upregulation of LncRNA PANDAR predicts poor prognosis and promotes cell proliferation in cervical cancer [J]. Eur Rev Med Pharmacol Sci，2017，21（20）：4529-4535.
[19] Zou Y，Zhong Y，Wu J，et al. Long non-coding PANDAR as a novel biomarker in human cancer：A systematic review [J]. Cell Prolif，2018，51（Suppl 7）：e12422.
[20] Zhan Y，Lin J，Liu Y，et al. Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer [J]. J Exp Clin Cancer Res，2016，35（1）：83.
[21] Wang H，Fang L，Jiang J，et al. The Cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation [J]. Cell Death Dis，2018，9（11）：1103. |
|
|
|
